Clinical Trial Update: AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance [Phase 3]

View source ↗

Summary

Phase 3 trial update in AML patients with FLT3 mutations evaluating peripheral blast clearance.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto | Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation | Phase 3 | Status: UNKNOWN